Prolonged QT interval and torsades de pointes associated with atazanavir therapy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 17304444.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We report, to our knowledge, the first documented case of torsades de pointes associated with atazanavir therapy. This case serves to highlight the need to monitor patients receiving atazanavir therapy who have risk factors for QT interval prolongation, such as female sex, bradycardia, electrolyte abnormalities, congestive heart failure, and a baseline prolonged QT interval.
Medical subject headings
- HIV Protease Inhibitors
- Long QT Syndrome
- Oligopeptides
- Pyridines
- Torsades de Pointes